For decades treatment of schizophrenia was restricted to drugs, which mainly target positive symptoms by interfering
with the dopaminergic neurotransmission.
Since a large body of experimental and clinical data implicate that schizophrenia may primarily be a consequence of an
imbalance in the glutamatergic system, specifically the networks containing GABAergic interneurons (γ-amino butyric
acid), new drugs modulating glutamatergic neurotransmission are being developed. Targeting this dysfunction may follow
different strategies, including application of direct or indirect NMDA (N-methyl-D-aspartate) receptor agonists or drugs
modulating the function of metabotropic glutamate receptors. Meanwhile, the first substances have proven to be effective
in animal models of schizophrenia and now enter the stage of clinical trials. The most promising data have been obtained
in studies employing agonists of the metabotropic glutamate receptor. A choice of these substances is presented in this review.
Keywords: Schizophrenia, Treatment, Glutamatergic system, NMDA receptor, Metabotropic Glutamate receptors, GABAergic
interneurons, glutamatergic neurotransmission, "drugs
modulating", metabotropic glutamate receptors, animal models
Rights & PermissionsPrintExport